Today: 11 June 2026
AMD stock rises as TSMC outlook lifts chips, even as Trump’s AI-tariff clouds the next trade
15 January 2026
2 mins read

AMD stock rises as TSMC outlook lifts chips, even as Trump’s AI-tariff clouds the next trade

NEW YORK, Jan 15, 2026, 16:09 ET — After-hours

  • AMD climbed roughly 2% in regular hours, hitting $238 at its peak during the session
  • Chip stocks got a lift after TSMC reported better-than-expected profits and unveiled a bigger spending plan for 2026
  • A newly imposed U.S. tariff on specific AI chips stirs uncertainty right before AMD’s Feb. 3 earnings report

Advanced Micro Devices (NASDAQ: AMD) climbed 1.9% on Thursday, fueled by a late-session rally sparked by renewed optimism over chip demand. Shares of AMD last stood at $227.76, after reaching an intraday peak of $238.33, with roughly 50 million shares traded. Nvidia advanced 2.1%, while Intel slipped 0.9%.

This matters as investors weigh two opposing factors: robust signals from the AI hardware supply chain and new U.S. trade restrictions targeting top-tier processors. AMD finds itself caught in the crossfire, offering data-center CPUs and AI accelerators but depending on overseas manufacturing.

This follows a shaky stretch for tech, as investors pulled back from expensive stocks and the Nasdaq fell 1% on Wednesday. Chip shares have been particularly volatile, given their sensitivity to changes in AI spending and chip demand, which usually hit that sector first.

Taiwan Semiconductor Manufacturing Co, a vital chip designer supplier, expects revenue in 2026 to jump nearly 30%, with capital spending forecast between $52 billion and $56 billion. The company said customers are sending “strong signals” and pushing for more capacity. CEO C.C. Wei admitted they’re “very nervous” about the scale of the expansion. Meanwhile, Quilter Cheviot’s Ben Barringer noted TSMC “ultimately benefits” as chipmakers battle for market share. Reuters

Trade policy just threw a curveball. On Wednesday, President Donald Trump slapped a 25% tariff on select AI chips — including Nvidia’s H200 and AMD’s MI325X — citing national security after a Section 232 probe. The White House clarified the tariff won’t hit chips brought in for U.S. data centers and a few other uses. AMD responded, saying, “We comply with all U.S. export control laws and policies.” Reuters

Wall Street sentiment on AMD has shifted more bullish this week. John Vinh, analyst at KeyBanc Capital Markets, upgraded AMD to “overweight” and bumped his price target up to $270. He highlighted growing demand from hyperscale cloud providers, the largest players in data centers, for AMD’s server CPUs. Vinh noted AMD is nearly “completely sold out” of its 2026 capacity and is eyeing a potential 10% to 15% price hike on server CPUs in Q1. MarketWatch

Earlier this week, AMD gained momentum following KeyBanc’s upgrade, with investors weighing fresh inflation figures alongside the kickoff of the U.S. earnings season.

AMD goes head-to-head with Nvidia in AI accelerators—those specialized chips that boost AI model training and execution—and squares off against Intel in server processors. For investors, the key concern isn’t just demand, but whether supply chains can keep up without hiccups.

The risk lies buried in the policy details. The new tariff order doesn’t clarify how widely performance benchmarks will be enforced, the speed at which exemptions might be approved, or if additional semiconductor duties will come next. Any of those moves could squeeze margins or disrupt delivery schedules.

Investors will zero in on AMD’s commentary about data-center demand, pricing, and margins when the company reports. They’ll also be watching to see if trade policy shifts from a mere headline to an actual expense.

AMD plans to release its fiscal fourth-quarter and full-year 2025 earnings on Feb. 3 after the market closes, followed by a conference call at 5 p.m. EST. This report is expected to be the next major trigger for the stock.

Stock Market Today

  • North Atlantic Smaller Companies Investment Trust PLC AGM Results June 2026
    June 11, 2026, 10:59 AM EDT. North Atlantic Smaller Companies Investment Trust PLC (NASCIT) announced at its 11 June 2026 Annual General Meeting that all resolutions were passed with strong shareholder support. Key was Resolution 16, approved by 97.31%, allowing the Concert Party's shareholding to increase from 32.467% to a maximum of 36.074% without triggering a mandatory offer, following a share buyback authorized by Resolution 14. Total votes cast showed overwhelming majority approval, with most resolutions receiving above 95% support. This vote impacts NASCIT's share structure and potential control dynamics. The company can continue its share repurchase strategy while managing shareholder interests.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Previous Story

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Talen Energy stock jumps after $3.45 billion natural-gas plant deal lifts PJM bet
Next Story

Talen Energy stock jumps after $3.45 billion natural-gas plant deal lifts PJM bet

Go toTop